Angle PLC - medical diagnostics company - Says its 200-patient ovarian cancer clinical verification study has completed patient enrolment. The study, undertaken by the University of Rochester Medical Center Wilmot Cancer Institute, New York, US, is designed to evaluate the use of Angle's Parsortix system for circulating tumour cell harvest and subsequent downstream analysis with Angle's HyCead multiplex RNA platform as a simple blood test to detect the presence of ovarian cancer in women with a pelvic mass prior to surgery. Once the new performance data is available, and assuming positive results, Angle intends to establish this test as a laboratory developed test for discriminating malignant from benign pelvic masses prior to surgery. Headline results from the study are expected in the fourth quarter of 2021.
Current stock price: 114.78 pence, up 1.6% on Monday
Year-to-date change: more than doubled from 47.75p on December 31
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Angle (AGL)